Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.4K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.4K
Aging01:26

Aging

975
Aging is a complex biological phenomenon influenced by various processes that affect cellular and systemic functions. Several prominent theories attempt to explain its mechanisms, highlighting cellular limitations, oxidative damage, and hormonal changes as central factors in aging.
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
975
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

2.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
The Effect of Aging on Tissues01:19

The Effect of Aging on Tissues

4.1K
Several body functions deteriorate with age. The external signs of aging are easily identifiable. For example, the skin becomes dry, less elastic, and thins out, forming wrinkles. The skin of the face begins to appear looser due to a decrease in the levels of elastic and collagen fibers in the connective tissue. Additionally, melanin production in the hair follicle decreases with age, resulting in gray hair. Moreover, the senses of sight and hearing decline, so glasses and hearing aids may...
4.1K
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

345
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
345
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

314
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
314

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registry.

Journal of neurology·2026
Same author

Oxylipin Biomarkers of Auto-Oxidation Are Associated with Antioxidant Micronutrients and Multiple Sclerosis Disability.

Antioxidants (Basel, Switzerland)·2026
Same author

Diffusion tensor imaging along the perivascular space and disease progression in people with multiple sclerosis: a 5-year longitudinal MRI study.

Brain communications·2026
Same author

Lower vascular cerebral flow and cerebral perfusion may be associated with impairment of the glymphatic system in multiple sclerosis: A cross-sectional DTI-ALPS MRI study.

Journal of the neurological sciences·2025
Same author

Real-world effectiveness of horizontal switching between disease-modifying therapies in multiple sclerosis: a retrospective analysis of the MSBase Registry.

Therapeutic advances in neurological disorders·2025
Same author

Auditory test of processing speed: Further validation and test-retest reliability.

Multiple sclerosis and related disorders·2025
Same journal

Association of epiretinal membranes with disability in people with multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Epiretinal membranes in multiple sclerosis: A window into glial pathobiology?

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Profiling the long-term risk of severe adverse events in a cohort of multiple sclerosis patients treated with different treatment sequences: Results from the Italian Multiple Sclerosis and Related Disorders Registry (I-MS&RD) (ProSA study).

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

UK consensus on pregnancy in multiple sclerosis: An update to 'Association of British Neurologists' guidance.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Comparative effectiveness of rituximab versus ocrelizumab in relapsing multiple sclerosis on clinical relapses and radiological outcomes in British Columbia, Canada.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Invisible symptoms in multiple sclerosis and their impact on social role participation: A multidimensional analysis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
See all related articles

Related Experiment Video

Updated: Mar 25, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.2K

Aging and multiple sclerosis.

Shaik Ahmed Sanai1, Vasu Saini2, Ralph Hb Benedict2

  • 1Jacobs Comprehensive MS Treatment and Research Center, University at Buffalo, The State University of New York, Buffalo, NY, USA.

Multiple Sclerosis (Houndmills, Basingstoke, England)
|February 21, 2016
PubMed
Summary
This summary is machine-generated.

The aging multiple sclerosis (MS) population is growing due to better treatments and comorbidity management. This review examines aging

Keywords:
Agingcomorbiditiesmultiple sclerosis

More Related Videos

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

10.1K
The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.9K

Related Experiment Videos

Last Updated: Mar 25, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.2K
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

10.1K
The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.9K

Area of Science:

  • Neurology
  • Gerontology
  • Immunology

Background:

  • Multiple sclerosis (MS) patient life expectancy and average age have risen significantly.
  • Disease-modifying therapies and improved comorbidity understanding contribute to an aging MS population.
  • Healthcare providers must manage age-related issues in chronic neurological disease.

Purpose of the Study:

  • To review the physiology of aging in the context of multiple sclerosis.
  • To explore the effects of aging on MS disease course, pathology, and immunology.
  • To discuss comorbidities in aging MS patients and diagnostic challenges.

Main Methods:

  • Literature review focusing on aging physiology and MS.
  • Analysis of pathological and immunological changes in aging and MS progression.
  • Discussion of common comorbidities and therapeutic differentiation challenges.

Main Results:

  • Aging significantly impacts the course and presentation of multiple sclerosis.
  • Distinguishing age-related changes from MS progression is complex.
  • Comorbidities in aging MS patients require careful assessment.

Conclusions:

  • Effective management of aging individuals with MS necessitates understanding the interplay between aging and the disease.
  • Differentiating age-related conditions from MS progression is crucial for tailored therapeutic strategies.
  • Further research is needed to optimize care for the growing elderly MS population.